|
Kevin Trigani, PhD
|
Kevin is a fifth year PhD candidate in Chemical Engineering at the University of Pennsylvania, where his research focus is on using microfluidics to study blood biology and blood clotting events. Prior to graduate school, he completed his B.S. in Chemical Engineering from Johns Hopkins University, where he was a member of Tau Beta Pi (National Engineering Honor Society).
Outside of academia, Kevin has completed a Co-op with Janssen Pharmaceuticals, where he worked in early CAR T cell process development. He also completed an internship with Celgene, where he used CRISPR/Cas9 to genetically modify natural killer cells to increase cytotoxicity against cancer cells.
Kevin is also a member of Penn Biotech Group (PBG) Consulting, a student-run pro bono consulting club at Penn, where he has served as a project manager and team member for a variety of clients, ranging from small University startups to top 10 biotech companies.
In his free time, Kevin enjoys traveling internationally, going to the beach, and exploring new restaurants in Philadelphia.
Outside of academia, Kevin has completed a Co-op with Janssen Pharmaceuticals, where he worked in early CAR T cell process development. He also completed an internship with Celgene, where he used CRISPR/Cas9 to genetically modify natural killer cells to increase cytotoxicity against cancer cells.
Kevin is also a member of Penn Biotech Group (PBG) Consulting, a student-run pro bono consulting club at Penn, where he has served as a project manager and team member for a variety of clients, ranging from small University startups to top 10 biotech companies.
In his free time, Kevin enjoys traveling internationally, going to the beach, and exploring new restaurants in Philadelphia.
